Guardant Health Q3 Revenue Rises 36% as Shield Blood Test Volume Surges 246% to 83,000Precision oncology and liquid biopsy innovator Guardant Health, Inc. (NASDAQ: GH) announced third-quarter financial results for fiscal 2026 on November 5, 2026, delivering substantial commercial…
FDA Approves Intravenous and Subcutaneous Atezolizumab for Stage III dMMR Colon Cancer Adjuvant TreatmentThe United States Food and Drug Administration finalized broad regulatory approval notices between November 6 and 8.
Edgewise Therapeutics Advances EDG-7500 into Phase 3 STRATUS-HCM with Echo-Free Dosing ProtocolClinical-stage biopharmaceutical company Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced on November 5, 2026, the successful completion of an End-of-Phase 2 regulatory meeting with the United…
FDA Extends PDUFA Review Timeline for Capricor's Deramiocel Cell Therapy in Duchenne Muscular Dystrophy to November 2026The United States Food and Drug Administration (FDA) formally announced an administrative extension of the Prescription Drug User Fee Act (PDUFA) target action date for Capricor Therapeutics' lead…
Bundibugyo Ebola Outbreak Confirmed in Democratic Republic of the Congo With 28 Cases as WHO Mobilizes ResponseThe World Health Organization and the Africa Centres for Disease Control and Prevention confirmed a recognized outbreak of Bundibugyo ebolavirus across the Democratic Republic of the Congo on…
argenx Announces Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis with sBLA Planned in 2026Biotechnology enterprise argenx SE officially presented landmark positive topline results on November 7, 2026, from its pivotal global Phase 3 ALKIVIA registrational study evaluating subcutaneous…
Ivonescimab Achieves 50.7% Pathological Complete Response in Resectable Lung Cancer TrialBiotechnology firm Akeso, Inc. (9926.HK) released updated findings from a prospective Phase II clinical trial on November 6, 2026, evaluating its first-in-class bispecific antibody ivonescimab…
NYU Langone Heart Presents Landmark Cardiovascular Findings on Chronic Kidney Disease at AHA Scientific Sessions 2026Cardiologists from the Leon H. Charney Division of Cardiology at NYU Langone Health presented findings on November 7 during the American Heart Association Scientific Sessions 2026 in Chicago.
FDA Investigates Severe Tumor and Malignancy Risks Linked to Novartis Zolgensma Gene TherapyHealth Regulators Scrutinize Vector Integration into Oncogenic GLI1 Gene Following Nine Documented Neoplasms in SMA Patients Investigating Regulatory Agency: U.S.
Teva Rolls Out Weltruza as First Once-Monthly Subcutaneous Olanzapine for Schizophrenia Free of 3-Hour PDSS MonitoringTeva Pharmaceuticals officially announced the widespread commercial deployment of Weltruza (olanzapine extended-release injectable suspension) for the treatment of adults with schizophrenia on…
Washington State Confirms First US Avian Influenza Death of 2026 Linked to Dairy Cattle as Outbreak Hits 33 HerdsThe Centers for Disease Control and Prevention (CDC) and the Washington State Department of Health officially confirmed the first human fatality from avian influenza A(H5N1) in the United States in…
Swiss Biotech iOnctura Unveils SITC 2026 Data on Roginolisib Overcoming Immunotherapy Resistance in Lung CancerSwiss clinical-stage oncology biopharmaceutical developer iOnctura announced breakthrough multi-center Ib/II clinical trial results at the 41st Annual Meeting of the Society for Immunotherapy of…
Roche Obtains FDA 510(k) Clearance for Cobas Eplex RP3 Respiratory Panel Detecting 19 Pathogens in Under 2 HoursRoche Diagnostics officially announced on November 6, 2026, that it has secured 510(k) market clearance from the United States Food and Drug Administration for its next-generation cobas eplex…
US State Attorneys General Secure Up to $10M Settlement in Perry Johnson Medical Data BreachAttorneys general from New York, New Jersey, Connecticut, and Michigan formally announced a comprehensive multi-state settlement on November 6, 2026, resolving enforcement investigations into medical…
PAHO Launches 4-Year Plan for Malaria Elimination in the Americas 2026-2030 in BrasiliaThe Pan American Health Organization (PAHO), serving as the Regional Office for the Americas of the World Health Organization (WHO), officially unveiled its landmark strategy document, the "Plan of…
PAHO Launches Five-Year Strategic Plan to Accelerate Malaria Elimination Across the AmericasOperational Horizon: 2026 through 2030 (Five-Year Implementation Cycle)；Spans 21 malaria-endemic nations in the Americas Strategic Vision: Achieve a "Zero Malaria Americas" regional status；Guides…
FDA Grants Orphan Drug Designation to Octant's OCT-980 for Retinitis PigmentosaClinical-stage biotechnology enterprise Octant, Inc., a pioneer in high-throughput synthetic biology and multiplexed cellular drug discovery platforms, officially announced on November 6, 2026, that…
Novo Nordisk Reports Real-World AASLD 2026 Clinical Data Demonstrating 63% MASH Resolution for Semaglutide 2.4 mg Outperforming ResmetiromKey Comparative Clinical Metrics: Semaglutide vs. Resmetirom in MASH Cohorts Alanine Aminotransferase (ALT) Reduction: -42.5% Mean Circulating Transaminase Reduction Evaluated Multi-Center Patient…
FDA Clears Access MeMed BV Assay Providing 15-Minute Blood Test to Distinguish Bacterial and Viral InfectionsDiagnostic Turnaround Time: Generates quantified probability score within 15 minutes；Validated on Beckman Coulter DxI 9000 analyzers Approved Clinical Cohort: Adult and pediatric patients aged 90…
CDC Weekly Surveillance Reports US Measles Cases Surpassing 5,182 With Deaths in 3 StatesThe Centers for Disease Control and Prevention (CDC) released its latest nationwide infectious disease surveillance update on November 6, 2026, revealing that cumulative confirmed measles cases…
FDA Accepts Resubmitted NDA for Rivoceranib Plus Camrelizumab in First-Line Liver Cancer Setting April 2027 PDUFA DateThe United States Food and Drug Administration formally accepted the resubmitted New Drug Application and Biologics License Application for the combination regimen of oral VEGFR inhibitor rivoceranib…
American Heart Association and Harvard Trials Deconstruct Intermittent Fasting: Weight Loss Governed by Behavior Not MetabolismThe American Heart Association and the Harvard T.H. Chan School of Public Health published an extensive multi-center meta-review in early November 2026 deconstructing popular intermittent fasting…
Swinburne University Study Confirms Broccoli Compound Sulforaphane Restores Frataxin to Treat Friedreich AtaxiaNeuroscience investigators from Swinburne University of Technology in Melbourne announced a major therapeutic milestone on November 7, 2026, confirming that sulforaphane—a natural phytochemical…
Eli Lilly Expands Partnership with Hims & Hers to Distribute FDA-Approved Branded Medicines OnlineGlobal pharmaceutical leader Eli Lilly and Company announced a major commercial expansion with personalized digital health platform Hims & Hers Health on November 6, 2026, broadening…
CMS Releases CY 2027 Medicare Physician Fee Schedule and ASC Rules, Trimming Cataract Pay by 4%The Centers for Medicare & Medicaid Services (CMS) officially released its final policy changes and payment rates for the Calendar Year (CY) 2027 Medicare Physician Fee Schedule (MPFS) alongside the…
FDA Grants Priority Review to Regeneron's Cemdisiran for Myasthenia Gravis After Phase 3 NIMBLE Trial SuccessThe U.S. Food and Drug Administration granted Priority Review in early November 2026 to Regeneron Pharmaceuticals' investigational small interfering RNA (siRNA) therapeutic cemdisiran for adult…
Agenus Discloses Landmark Long-Term Survival Data for BOT+BAL Immuno-Oncology Regimen at SITC 2026 Demonstrating 51% 18-Month Survival in MSS Colorectal CancerKey Clinical Trial Metrics: BOT+BAL Regimen in Refractory MSS Colorectal Cancer Refractory MSS mCRC Patient Cohort: 123 Heavily Pretreated Patients (No Active Liver Mets) 18-Month Long-Term Survival…
American Academy of Pediatrics Overhauls Pediatric Screen Guidelines Prioritizing Content Quality Over Arbitrary Time LimitsWhat Quantitative Benchmarks Anchor the AAP Pediatric Digital Guidelines? Adolescent Social Media Penetration: Approximately 92% active on digital networks Mean Age of First Mobile Device Access:…
Imperial College Spinout OSSTEC Raises $8 Million for 3D Bone Implants as The Lancet Discloses Landmark Trial for Cardiovascular TherapyKey Clinical and Financial Benchmarks: OSSTEC Venture and Lancet Trial OSSTEC Series A Equity Financing Total: $8.0 Million USD (Innovate UK Co-Investment) Bio-Active Titanium Osseointegration Rate:…
FDA Approves Xbrane's Lucamzi (ranibizumab-blrz) Biosimilar to Lucentis for Wet AMDThe U.S. Food and Drug Administration (FDA) officially approved Lucamzi (ranibizumab-blrz), a high-quality biosimilar to reference biologic Lucentis (ranibizumab, developed by Genentech/Roche and…
Okogen Doses First Patient in Phase 1/2 EMERALD Trial of Treyegen for Acute Infectious ConjunctivitisClinical-stage biotechnology firm Okogen, Inc. announced on November 5, 2026, that the first patient has been officially dosed in the EMERALD trial, a pivotal multicenter Phase 1/2 clinical study…
UK NHS Launches World-First STRIDE-RCT Multi-Cancer Early Detection Blood Test Trial Across 200 Primary Care ClinicsDeploying Liquid Biopsy Platforms Across 200 Primary Care Hubs for Undifferentiated Symptoms In conventional clinical oncology, non-specific abdominal complaints—such as persistent bloating,…
Nacuity Doses First Patient in Global Phase 3 Trial of Oral NPI-001 for Usher Syndrome Retinitis PigmentosaNacuity Pharmaceuticals, Inc., a clinical-stage ophthalmology biopharmaceutical enterprise dedicated to developing breakthrough treatments for blinding retinal diseases, announced on November 5,…
FX Shoulder Solutions Makes History with FDA 510(k) Clearance for Easytech Reversed Stemless SystemFX Shoulder Solutions, Inc., a rapidly expanding orthopedic medical technology innovator headquartered in Addison, Texas, officially announced on November 5, 2026, that it has received landmark…
FDA Grants Fast Track Designation to Front Range Pharmaceuticals' FRP-003 for Long COVIDThe U.S. Food and Drug Administration's (FDA) Division of Rheumatology and Transplant Medicine granted Fast Track designation on November 6, 2026, to Front Range Pharmaceuticals' investigational oral…
FDA Grants Accelerated Approval to J&J’s Rybrevant Faspro for Advanced Head and Neck CancerBispecific Subcutaneous Formulation Breaks Decade-Long Therapeutic Drought in Advanced HNSCC The landmark regulatory decision resolves a protracted decade-long therapeutic stagnation in post-platinum…
CMS Finalizes 2027 Medicare Physician Fee Schedule, Cutting Base Conversion Factor by 2.31%The Centers for Medicare & Medicaid Services (CMS) officially released its final rule for the Calendar Year 2027 Medicare Physician Fee Schedule (PFS) on November 4, 2026, implementing a 2.31%…
Cloudbreak Pharma's CBT-001 Meets All Primary Endpoints in Pivotal Phase 3 Pterygium Eye Drop TrialCloudbreak Pharma Inc., a clinical-stage biopharmaceutical innovator headquartered in Irvine, California, officially announced positive top-line data from its global pivotal Phase 3 clinical trial…
Altimmune Presents Landmark RECLAIM Phase 2 Data: Pemvidutide Drastically Reduces Heavy Drinking Days in AUDAltimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical leader advancing next-generation peptide therapeutics, officially presented comprehensive top-line data from its 24-week RECLAIM…
Long COVID Recovery Varies by Symptoms: About Half Improve by Year ThreeA three-year US follow-up study A study published in the Annals of Internal Medicine found that symptoms can continue to improve years after a person develops Long COVID, although improvement does…
Study Suggests Drug-and-Vibration Approach May Help Move Proteins Out of the Brain, but It Is Not a Dementia TreatmentResearchers at the University of Oulu in Finland reported on Nov. 3 that an experimental combination of a blood-vessel-dilating drug and targeted whole-body vibration may increase the movement of…
England Launches Multi-Cancer Blood-Test Trial for More Than 20,000 NHS Patients in Primary CareThe UK government has announced STRIDE-RCT, a clinical trial that will recruit more than 20,000 NHS patients through at least 200 general practices in England.
Frequent and Unintentional Daytime Napping Linked to Higher Dementia Risk in Older AdultsResearchers at the Johns Hopkins Bloomberg School of Public Health found that frequent or unintentional daytime napping among older adults was associated with a higher risk of developing dementia…
Energy Drinks Linked to More Cardiac-Arrest Reports in Young Adults, but Study Does Not Prove CauseA preliminary study from the American Heart Association found that reports of cardiac arrest appeared about 11 times more often in connection with caffeinated energy drinks and stimulant supplements…
Africa CDC Warns of Unprecedented Ebola Spread and Urges Countries to PrepareJean Kaseya, head of the Africa Centres for Disease Control and Prevention, has warned that the geographic spread of the current Ebola outbreak is unprecedented and that countries should increase…
US Midterms Could Shift Sector Expectations, Putting AI, Energy and Healthcare in FocusUS Midterms Could Shift Sector Expectations, Putting AI, Energy and Healthcare in Focus The US midterm elections will determine control of Congress, but they may also change the regulatory, spending…
FDA Classifies Recall of 3,744 Bottles of Combination Blood Pressure Drug as Class II After Dissolution Test FailureFDA Classifies Recall of 3,744 Bottles of Combination Blood Pressure Drug as Class II After Dissolution Test Failure The U.S.
Ebola Outbreak Death Toll Tops 5,300, With Most Deaths in the Democratic Republic of the CongoThe death toll from the latest Ebola outbreak in Africa has exceeded 5,300, according to figures reported by the Africa Centres for Disease Control and Prevention.
CVS Plans to Separate Its Pharmacy and Insurance BusinessesA reversal of its integrated healthcare strategy One company would retain the CVS Health name and combine Aetna, pharmacy-benefit manager Caremark, Oak Street Health clinics, Signify Health home-care…
Roger Marshall Bets His Kansas Closing Argument on Defending Patient LawsuitsRoger Marshall Bets His Kansas Closing Argument on Defending Patient Lawsuits With Election Day hours away, Senator Roger Marshall, Republican of Kansas, made his treatment of patients the…